Vaccine Development for Prescottella Equi

Thirumahal Vanniasinkam; C Giles; S Ndi; M Heuzenroeder; M Barton

doi:10.1016/j.provac.2014.07.009

Vaccine Development for Prescottella Equi

Thirumahal Vanniasinkam, C Giles, S Ndi, M Heuzenroeder, M Barton

Research output: Book chapter/Published conference paper › Conference paper › peer-review

42 Downloads (Pure)

Abstract

Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.

Original language	English
Title of host publication	Procedia in Vaccinology
Subtitle of host publication	7th Vaccine & ISV Annual Global Congress
Editors	Ray Spier
Place of Publication	Netherlands
Publisher	Elsevier
Pages	50-57
Number of pages	8
Volume	8
DOIs	https://doi.org/10.1016/j.provac.2014.07.009
Publication status	Published - 2014
Event	7th Vaccine & ISV Congress - Meliá Sitges, Sitges, Barcelona, Spain Duration: 27 Oct 2013 → 29 Oct 2013 https://www.isv-online.org/menu-annual-congress/previos-congress/7th-global-congress-oral-programme

Publication series

Name
ISSN (Print)	1877-282X

Conference

Conference	7th Vaccine & ISV Congress
Country/Territory	Spain
City	Sitges, Barcelona
Period	27/10/13 → 29/10/13
Internet address	https://www.isv-online.org/menu-annual-congress/previos-congress/7th-global-congress-oral-programme

Access to Document

10.1016/j.provac.2014.07.009

1000001284_pub in full.pdfAccepted author manuscript, 230 KB

Cite this

@inproceedings{498cc812be32406892ce7072e46bd054,

title = "Vaccine Development for Prescottella Equi",

abstract = "Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.",

keywords = "Open access version available, Prescottella equi, Rhodococcus equi, vaccine, VapA",

author = "Thirumahal Vanniasinkam and C Giles and S Ndi and M Heuzenroeder and M Barton",

note = "Imported on 16 May 2017 - DigiTool details were: publisher = Netherlands: Elsevier, 2014. editor/s (773b) = Ray Spier; Event dates (773o) = 27 -29 October 2013; Volume no. (773r) = 8; Parent title (773t) = Vaccine & ISV Congress. ISSNs: 1877-282X; ; 7th Vaccine & ISV Congress ; Conference date: 27-10-2013 Through 29-10-2013",

year = "2014",

doi = "10.1016/j.provac.2014.07.009",

language = "English",

volume = "8",

publisher = "Elsevier",

pages = "50--57",

editor = "Ray Spier",

booktitle = "Procedia in Vaccinology",

address = "Netherlands",

url = "https://www.isv-online.org/menu-annual-congress/previos-congress/7th-global-congress-oral-programme",

}

TY - GEN

T1 - Vaccine Development for Prescottella Equi

AU - Vanniasinkam, Thirumahal

AU - Giles, C

AU - Ndi, S

AU - Heuzenroeder, M

AU - Barton, M

N1 - Imported on 16 May 2017 - DigiTool details were: publisher = Netherlands: Elsevier, 2014. editor/s (773b) = Ray Spier; Event dates (773o) = 27 -29 October 2013; Volume no. (773r) = 8; Parent title (773t) = Vaccine & ISV Congress. ISSNs: 1877-282X;

PY - 2014

Y1 - 2014

N2 - Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.

AB - Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.

KW - Open access version available

KW - Prescottella equi, Rhodococcus equi, vaccine, VapA

U2 - 10.1016/j.provac.2014.07.009

DO - 10.1016/j.provac.2014.07.009

M3 - Conference paper

VL - 8

SP - 50

EP - 57

BT - Procedia in Vaccinology

A2 - Spier, Ray

PB - Elsevier

CY - Netherlands

T2 - 7th Vaccine & ISV Congress

Y2 - 27 October 2013 through 29 October 2013

ER -

Vaccine Development for Prescottella Equi

Abstract

Publication series

Conference

Access to Document

Fingerprint

Cite this